CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes-Reference-Cited by-同舟云学术

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes

Published:2021-11-30 Issue:23 Volume:5 Page:4963-4968
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Huang Benjamin J.¹²^ORCID,Smith Jenny L.³,Wang Yi-Cheng⁴,Taghizadeh Kassra³,Leonti Amanda R.³,Ries Rhonda E.³,Liu Yanling⁵,Kolekar Pandurang⁵^ORCID,Tarlock Katherine³⁶,Gerbing Robert⁴,Crowgey Erin⁷^ORCID,Furlan Scott N.³⁶,Shaw Timothy I.⁵^ORCID,Hagiwara Kohei⁵,Wei Lisa⁸,Cooper Todd M.⁶,Gamis Alan S.⁹^ORCID,Aplenc Richard¹⁰^ORCID,Kolb E. Anders⁷,Farrar Jason E.¹¹^ORCID,Triche Timothy¹²,Alonzo Todd A.¹³,Ma Xiaotu⁵,Meshinchi Soheil³⁶

Affiliation:

1. Department of Pediatrics, University of California San Francisco, San Francisco, CA;

2. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;

3. Fred Hutchinson Cancer Research Center, Seattle, WA;

4. Children's Oncology Group, Monrovia, CA;

5. Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN;

6. Division of Hematology/Oncology, Seattle Children’s Hospital, Seattle, WA;

7. Nemours Center for Cancer and Blood Disorders and Alfred I. DuPont Hospital for Children, Wilmington, DE;

8. Michael Smith Genome Sciences Centre, Vancouver, BC, Canada;

9. Children's Mercy Hospitals and Clinics, Kansas City, MO;

10. Children’s Hospital of Philadelphia, Philadelphia, PA;

11. University of Arkansas for Medical Sciences & Arkansas Children's Research Institute, Little Rock, AR;

12. Van Andel Research Institute, Grand Rapids, MI; and

13. Department of Preventive Medicine, University of Southern California, Los Angeles, CA

Abstract

Key Points CBFB-MYH11 transcripts and KIT mutations predict relapse in AML. High-risk CBFB-MYH11 transcripts are associated with distinct transcriptional landscapes and upregulation of early hematopoiesis genes.

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/5/23/4963/1847545/advancesadv2021004965.pdf

Reference35 articles.

1. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations;Schwind;Blood.,2013

2. Outcomes in CCG-2961, a Children’s Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group;Lange;Blood.,2008

3. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group;Cooper;Cancer.,2012

4. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531;Gamis;J Clin Oncol.,2014

5. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group;Aplenc;Haematologica.,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML;2023-09-23

2. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication;Nature Communications;2023-04-05

3. Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia;Haematologica;2023-02-23

4. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia;Nature Communications;2022-09-19